How immune cells help reduce inflammation in premature infants
Regulation of neonatal inflammation by myeloid-derived suppressor cells
['FUNDING_R01'] · WISTAR INSTITUTE · NIH-10610350
This study is looking at how certain immune cells in very premature babies can help reduce inflammation and protect them from serious health issues, with the goal of finding better ways to keep these tiny infants healthy.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WISTAR INSTITUTE (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10610350 on ClinicalTrials.gov |
What this research studies
This research investigates the role of myeloid-derived suppressor cells (MDSC) in managing inflammation in extremely preterm infants, who are at high risk for severe conditions like bronchopulmonary dysplasia, necrotizing enterocolitis, and sepsis. The study aims to understand how these immune cells can protect newborns from infections and inflammatory injuries. By examining the accumulation and function of MDSC in preterm infants, the researchers hope to uncover new therapeutic strategies that could improve health outcomes for this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are extremely preterm infants, particularly those born with a high risk of developing bronchopulmonary dysplasia, necrotizing enterocolitis, or sepsis.
Not a fit: Patients who are not preterm or those who do not have conditions related to inflammation or immune dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce mortality and morbidity in extremely preterm infants.
How similar studies have performed: Other research has shown promising results regarding the role of immune cells in managing inflammation, suggesting that this approach could be beneficial.
Where this research is happening
PHILADELPHIA, UNITED STATES
- WISTAR INSTITUTE — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NEFEDOVA, YULIA — WISTAR INSTITUTE
- Study coordinator: NEFEDOVA, YULIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease